RGNX REGENXBIO Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1590877 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.6%
TTM net income YoY1.5%
TTM EPS YoY7.5%
Revenue 3-yr CAGR15.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-95.7%
Net margin-113.9%
FCF margin-100.6%
EBITDA margin-85.9%
Returns
ROE-113.2%
ROA-35.4%
ROIC (approx.)-150.2%
Asset turnover0.31x
Leverage & solvency
Liabilities / assets68.2%
Debt / equity0.00x
Current ratio4.74x
Interest coverage-4.06x
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-4.7%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $170.44M | $83.33M |
| Cost of revenue | — | $33.57M |
| Gross profit | — | $49.76M |
| R&D expense | $228.30M | $208.52M |
| SG&A expense | $82.86M | $76.62M |
| Operating income | -$161.20M | -$233.35M |
| Interest expense | $45.01M | $12.66M |
| Pretax income | -$193.88M | -$227.10M |
| Income tax | $0 | $0 |
| Net income | -$193.88M | -$227.10M |
| EBITDA | -$145.58M | -$217.13M |
| EPS (basic) | -3.76 | -4.59 |
| EPS (diluted) | -3.76 | -4.59 |
| Weighted avg. shares (diluted) | 51.57M | 49.51M |
| Banking | ||
| Provision for credit losses | — | -$5.00M |
| Balance sheet | ||
| Cash & equivalents | $34.47M | $57.53M |
| Short-term investments | $195.60M | $177.16M |
| Receivables | $26.38M | $20.47M |
| Current assets | $281.28M | $278.00M |
| PP&E, net | $104.86M | $117.59M |
| Total assets | $453.03M | $465.99M |
| Current liabilities | $118.09M | $103.19M |
| Total liabilities | $350.30M | $206.34M |
| Shareholders' equity | $102.73M | $259.65M |
| Shares outstanding | 50.89M | 49.55M |
| Cash flow statement | ||
| Operating cash flow | -$123.96M | -$173.12M |
| Capital expenditure | $2.41M | $2.44M |
| Free cash flow | -$126.38M | -$175.56M |
| Investing cash flow | -$15.87M | $103.45M |
| Financing cash flow | $116.77M | $92.68M |
| Depreciation & amortization | $15.62M | $16.21M |
| Stock-based compensation | $34.56M | $38.46M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.